Log in

Relevant bibliographies by topics / Combination antihypertensive therapy multiple benefits / Journal articles

To see the other types of publications on this topic, follow the link: Combination antihypertensive therapy multiple benefits.

Journal articles on the topic 'Combination antihypertensive therapy multiple benefits'

Author: Grafiati

Published: 5 June 2025

Last updated: 2 August 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Combination antihypertensive therapy multiple benefits.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Gorokhova, T. V., and N. B. Perepech. "Potential of combination therapy in patients with hypertension and dyslipidemia." Russian Journal of Cardiology 27, no. 7 (2022): 5132. http://dx.doi.org/10.15829/1560-4071-2022-5132.

Full text

Abstract:

This article provides an overview of data on the role of hypertension and dyslipidemia as the leading factors determining the clinical course of athero sclerotic diseases. The need for a multifactorial approach to the treatment of patients with multiple risk factors for the progression of such diseases is noted. The article describes the results of large-scale international studies confirming the clinical benefits of combined antihypertensive and lipid-lowering therapy. From the point of view of current clinical guidelines and the available evidence base, the potential for improving adherence

APA, Harvard, Vancouver, ISO, and other styles

2

Chatzikyrkou, Christos, Hermann Haller, and Jan Menne. "Efficacy and safety of fixed-dose Lercanidipine-Enalapril for the treatment of hypertension." Clinical Medicine. Therapeutics 1 (January 2009): CMT.S2315. http://dx.doi.org/10.4137/cmt.s2315.

Full text

Abstract:

Hypertension is the most important preventable cause of premature death in the developed countries, and the benefits of antihypertensive drugs regarding cardiovascular morbidity and mortality are well established. Nevertheless, adequate control is achieved only in the minority of patients. All official guidelines recommend blood pressure targets of 140/90 mmHg in every patient and even lower in high-risk groups, and support the use of two of more drugs as initial therapy in specific populations. Multiple drugs acting by different, but complementary, mechanisms of action are increasingly implem

APA, Harvard, Vancouver, ISO, and other styles

3

Iqbal, Muzaffar. "Clinical Perspective on the Management of Hypertension." Indian Journal of Clinical Medicine 2 (January 2011): IJCM.S5475. http://dx.doi.org/10.4137/ijcm.s5475.

Full text

Abstract:

Hypertension is an important medical and public health issue all over the world. It is one of the most prevalent conditions seen today by clinicians in both developed and developing countries. Depending upon progression of systolic and diastolic blood pressure it is classified into stage 1, 2 and 3 hypertension. Life style modifications may be helpful in initial stage but pharmacological treatment is necessary when it become difficult to control it. In routine practice, pharmacological treatment is being selected from diuretics, β-blockers, calcium channel blockers and renin angiotensin system

APA, Harvard, Vancouver, ISO, and other styles

4

Kamal, Kamal Kant, Ashutosh Sharma, Mayank Bansal, and Vishal Choudhary. "Design and evaluation of bi-layered tablet of Ramipril and hydrochlorothiazide for the Treatment of hypertension." Journal of Biomedical and Pharmaceutical Research 14, no. 3 (2025): 38–41. https://doi.org/10.32553/jbpr.v14i3.1320.

Full text

Abstract:

Hypertension is a widespread cardiovascular disease that requires effective management through combination therapy. The complexity of hypertension necessitates a multifaceted approach, often involving the concurrent administration of multiple antihypertensive agents. This study aims to design, formulate, and evaluate bi-layered tablets of Ramipril and Hydrochlorothiazide, leveraging the benefits of sequential drug release and stability enhancement. The bi-layer tablet formulation comprises an immediate-release layer for rapid therapeutic onset and a sustained-release layer for prolonged plasma

APA, Harvard, Vancouver, ISO, and other styles

5

Chukaeva, I. I. "Adherence and benefits of full-dose combination of antihypertensive drugs." "Arterial’naya Gipertenziya" ("Arterial Hypertension") 18, no. 1 (2012): 46–51. http://dx.doi.org/10.18705/1607-419x-2012-18-1-46-51.

Full text

Abstract:

Control over blood pressure is an existing problem in cardiology and does not exceed 30 % for Europeans, despite prevalence and availability of effective antihypertensive drugs. Low adherence to treatment is one of the reasons of low control of blood pressure. Implementation of the combined antihypertensive drugs with the high fixed doses allows to simplify therapy in subjects receiving combination therapy and to increase the adherence in high risk patients receiving drugs separately.

APA, Harvard, Vancouver, ISO, and other styles

6

Minushkina, L. O. "COMBINATION THERAPY IN THE MANAGEMENT OF ARTERIAL HYPERTENSION: EFFECTIVENESS OF THE LERCANIDIPINE AND ENALAPRIL COMBINATION." Cardiovascular Therapy and Prevention 12, no. 5 (2013): 75–80. http://dx.doi.org/10.15829/1728-8800-2013-5-75-80.

Full text

Abstract:

This review presents the evidence on the benefits of fixed-dose combination therapy for arterial hypertension management. The focus is on the combination of a third-generation dihydropyridine calcium antagonist lercanidipine and an ACE inhibitor enalapril. Lercanidipine is characterised by high vascular selectivity and lipophilicity, good antihypertensive effectiveness, and prolonged, gradually developing therapeutic effects. Literature data on the effectiveness of the lercanidipine-enalapril combination are presented. This combination facilitates a marked reduction in blood pressure levels, w

APA, Harvard, Vancouver, ISO, and other styles

7

Petrova, M. M., O. P. Bobrova, and D. S. Kaskaeva. "Pharmacoeconomic issues of antihypertensive therapy in elderly patients (older than 75 years)." "Arterial’naya Gipertenziya" ("Arterial Hypertension") 17, no. 4 (2011): 361–65. http://dx.doi.org/10.18705/1607-419x-2011-17-4-361-365.

Full text

Abstract:

Objective. To carry out a pharmacoeconomic analysis of the antihypertensive therapy in elderly patients of high cardiovascular risk by the means of the method assessing «expenses - benefits», cost minimization, the increment of cost efficiency. Results. The cost of the daily efficient dose of the original (Renitec, MSD) and generic Enalapril (Hemofarm) was 6,54 and 7,25 rubles, respectively. Minimal coefficient «expenses - benefits» was defined in the group of patients receiving two drug combination therapy including original Enalapril (Renitec, MSD) compared to combination of three drugs incl

APA, Harvard, Vancouver, ISO, and other styles

8

Adonkina, Viktoriya, and Oksana Mishchenko. "Pharmacoeconomic evaluation of fixed-dose triple combination for antihypertensive therapy in Ukraine." Journal of Health Policy & Outcomes Research, no. 1 (August 14, 2014): 66–75. http://dx.doi.org/10.7365/jhpor.2014.5.8.

Full text

Abstract:

In Ukraine, the efficacy of treatment of arterial hypertension is only 19% in urban areas and 8 % in rural populations. The most important reasons of low efficiency of antihypertensive therapy (AHT) are a wrong choice of tactics of the patient management and low adherence of patients to treatment. The latter decreases with increasing amounts of prescribed drugs. One possible way to increase patients’ compliance to treatment and the effectiveness of therapy is to use fixed-dose combinations (FDCs) of antihypertensive drugs (AHDs). The share of FDCs consumption (in terms of DDDs/1000/day) in Ukr

APA, Harvard, Vancouver, ISO, and other styles

9

Morozova, T. E., T. B. Andrushchishina, and I. Yu Yudina. "Combined pharmacotherapy of arterial hypertension. Overview fixed combination antihypertensive drugs." Systemic Hypertension 13, no. 3 (2016): 58–63. http://dx.doi.org/10.26442/sg29153.

Full text

Abstract:

Hypertension remains the cornerstone of the cardiovascular continuum. An increasing number of patients receive a combination antihypertensive therapy to achieve target blood pressure, expanding indications for combination therapy at the onset of treatment. Constantly growing market of fixed combinations (FC) of antihypertensive drugs. The article gives an overview of the FC, registered in the Russian Federation, discussed the clinical situation for the preferential destination of a FC. A more detailed analysis of FC comprising the angiotensin II receptor blocker and diuretics, in particular, d

APA, Harvard, Vancouver, ISO, and other styles

10

Nichol, Michael B., Jane E. Margolies, and Mark A. Gill. "Factors Associated with Antihypertensive Prescribing." Annals of Pharmacotherapy 31, no. 2 (1997): 154–59. http://dx.doi.org/10.1177/106002809703100203.

Full text

Abstract:

Objective To investigate factors associated with treatment approaches to hypertension, a major risk factor for coronary heart and cerebrovascular disease and a significant healthcare problem in the US. The study reports on three cross-sectional national surveys of patient–physician encounters. Population Visits were selected for adults with hypertension diagnoses from the National Ambulatory Medical Care Surveys, which represent office encounters during a given year. Years of observation included 1989, 1990, and 1991. Methods Multiple variable logistic regression was used to identify predispos

APA, Harvard, Vancouver, ISO, and other styles

11

Sonam, Dhrupthob. "Prescribing patterns of antihypertensive drugs by clinicians at the National Referral Hospital outpatient department, Thimphu, Bhutan." Bhutan Health Journal 10, no. 2 (2024): 1–5. http://dx.doi.org/10.47811/bhj.172.

Full text

Abstract:

Introduction: Around 1.28 billion adults aged 30-79 years have hypertension, globally. Of these, two-thirds are in low and middle-income countries, with only 21% having it under control. In Bhutan, there are 362.4 people per 10,000 population with hypertension. Antihypertensive medications must be appropriately prescribed to prevent the complications of hypertension. Methods: A cross-sectional study of the prescriptions of antihypertensive medications at Jigme Dorji Wangchuck National Referral Hospital was undertaken to characterize the current prescribing patterns. Results: Nine monotherapy,

APA, Harvard, Vancouver, ISO, and other styles

12

Narita, Keisuke, Satoshi Hoshide, and Kazuomi Kario. "Polypill Therapy for Cardiovascular Disease Prevention and Combination Medication Therapy for Hypertension Management." Journal of Clinical Medicine 12, no. 23 (2023): 7226. http://dx.doi.org/10.3390/jcm12237226.

Full text

Abstract:

Although various guidelines for cardiovascular disease prevention have been established, the optimal drug therapy is often not implemented due to poor medication adherence and the clinical inertia of healthcare practitioners. Polypill strategies are one solution to this problem. Previous studies have established the usefulness of polypills, i.e., combination tablets including three or more medications, for the prevention of cardiovascular disease. For this purpose, the polypills generally contain an antiplatelet medication, an antihypertensive medication, and a statin. For the specific managem

APA, Harvard, Vancouver, ISO, and other styles

13

Bubnova, Marina Gennad'evna. "Perspektivy klinicheskogo primeneniyanovoy fiksirovannoy kombinatsii -preparata Ko-Eksforzh v lecheniiarterial'noy gipertonii." CardioSomatics 2, no. 1 (2011): 64–71. http://dx.doi.org/10.26442/cs44978.

Full text

Abstract:

Summary. This review is concerned with improving of blood pressure (BP) control in patients with arterial hypertension (AH). The reasons for the low treatment compliance and combined antihypertensive therapy benefits are analyzed. Data for futility of an extended use of antihypertensive drugs (AHD) fixed combinations are given. Studies demonstrating high efficacy and safety of a new triple fixed combination of amlodipine, valsartan and hydrochlorothiazide (HCT) are presented as well. Patients with hypertension, which should more actively use this combination of drugs, are signified.

APA, Harvard, Vancouver, ISO, and other styles

14

PITT, B. "Extending the benefits of combination antihypertensive therapy to morbidity and mortality reduction." American Journal of Hypertension 18, no. 5 (2005): A268—A269. http://dx.doi.org/10.1016/j.amjhyper.2005.03.727.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

DAHLOF, B. "Extending the benefits of combination antihypertensive therapy to morbidity and mortality reduction." American Journal of Hypertension 17, no. 5 (2004): S248. http://dx.doi.org/10.1016/j.amjhyper.2004.03.661.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Pinchuk, Tatiana V., and Natalia V. Orlova. "The place of fixed antihypertensive drugs in modern therapy of arterial hypertension." Systemic Hypertension 17, no. 4 (2021): 44–48. http://dx.doi.org/10.26442/2075082x.2020.4.200035.

Full text

Abstract:

The article provides information on modern approaches to the treatment of arterial hypertension. The historical information about therapy with combined antihypertensive drugs is given. Based on data from multicenter clinical trials, the article provides evidence of the benefits of dual and triple fixed drug combinations. Combinations of 1-adrenoreceptor antagonist bisoprolol and the dihydropyridine-type calcium channel blocker amlodipine are considered. The article highlights the advantages of each of the drugs, as well as their combination. It shows the benefits of a fixed combination of low

APA, Harvard, Vancouver, ISO, and other styles

17

Shrestha, Deepti, Shirish L. Shrestha, Rekha Poudel, Rashmi Shakya Gurung, Radhay Shyam Yadav, and Lava Shrestha. "Trend of Antihypertensive Use and Blood Pressure Control Among Hypertensive Patients in a Tertiary Care Hospital of Kathmandu." Journal of Institute of Medicine Nepal 44, no. 1 (2022): 35–39. http://dx.doi.org/10.59779/jiomnepal.1205.

Full text

Abstract:

Introduction: Hypertension is a global burden and prevalence of hypertension increases with age. Various antihypertensive drugs are available for the management of hypertension. The aim of this study is to assess the trend of antihypertensive drugs used and blood pressure (BP) control among patients with hypertension. Methods: A cross sectional study was conducted among patients with hypertension prescribed with antihypertensive drugs in Department of Medicine, Nepal Medical College Teaching Hospital. Antihypertensive drugs, number of antihypertensive drugs prescribed in each individual and BP

APA, Harvard, Vancouver, ISO, and other styles

18

Ostroumova, O. D., A. I. Kochetkov, V. N. Butorov, and I. F. Krotkova. "How to Choose the Optimal Single-Pill Combination of the First-Line Antihypertensive Drugs? The Benefits of Amlodipine and Telmisartan Combination." Rational Pharmacotherapy in Cardiology 16, no. 4 (2020): 614–22. http://dx.doi.org/10.20996/1819-6446-2020-07-01.

Full text

Abstract:

In patients with arterial hypertension (AH), an extremely important measure of the effectiveness of antihypertensive drugs (AHD) is not only a direct decrease in blood pressure (BP), but also its stable control throughout the 24 hours, preventing excessive morning surge and increased BP variability, which in turn are recognized cardiovascular risk factors. Currently, in the vast majority of hypertensive patients, the main antihypertensive therapy approach is using single-pill combinations (SPC) of AHD. Among the first-line combinations for a wide range of patients with AH and no special clinic

APA, Harvard, Vancouver, ISO, and other styles

19

Ramadhani, Novely Dwita, Primanitha Ria Utami, Devi Ristian Octavia, and Ekanita Desiani. "Comparison of Blood Pressure in Hypertensive Patients with Monotherapy and Combination Antihypertensive Therapy." Proceedings of International Pharmacy Ulul Albab Conference and Seminar (PLANAR) 3 (November 13, 2023): 103. http://dx.doi.org/10.18860/planar.v3i0.2476.

Full text

Abstract:

Background: Hypertension is a cardiovascular risk factor that is closely related to the patient's systolic and diastolic blood pressure profile. Objective: This study aims to determine the comparison of systolic and diastolic blood pressure profiles using antihypertensives in patients with cardiovascular risk factors. Method: Conducted in the period August-December 2021 on 83 patients who met the inclusion criteria, namely outpatients diagnosed with hypertension with cardiovascular risk factors, adult patients over 18 years of age, a medical record sheet, and a written prescription in full. Da

APA, Harvard, Vancouver, ISO, and other styles

20

Taratukhin, E. O., and N. V. Teplova. "COMBINATION ANTIHYPERTENSIVE THERAPY: WHEN THE WHOLE IS GREATER THAN THE SUM OF ITS PARTS." Cardiovascular Therapy and Prevention 12, no. 3 (2013): 68–71. http://dx.doi.org/10.15829/1728-8800-2013-3-68-71.

Full text

Abstract:

The paper discusses the importance of high treatment compliance in the case of long-term or life-long therapy. This problem can be resolved by the use of combination pharmacological treatment, such as the combination of a calcium channel blocker and an ACE inhibitor. Apart from the higher treatment compliance, this combination provides additional metabolic benefits, due to the beneficial metabolic effects of its components.

APA, Harvard, Vancouver, ISO, and other styles

21

Shehyan, G. G., A. A. Yalymov, A. M. Schikota, V. S. Zadionchenko, and S. I. Varentsov. "The telmisartan and amlodipine combination in the treatment of hypertension." Systemic Hypertension 11, no. 1 (2014): 64–72. http://dx.doi.org/10.26442/sg29014.

Full text

Abstract:

The following review assesses socially significant disease - hypertension (AH) - and the problem of finding an effective antihypertensive therapy. Twynsta® drug (manufacturer Boehringer Ingelheim Pharma) - modern combined antihypertensive drug, which not only provides effective blood pressure control, but also due to the protective effect has been proved for all target organs improves the life expectancy of patients with hypertension. The clinical studies show that combination of telmisartan and amlodipine provides additional benefits in the treatment of patients with metabolic syndrome (by im

APA, Harvard, Vancouver, ISO, and other styles

22

Bellone, Marco, and Pierluigi Sbarra. "A cost-minimization analysis of combination therapy in hypertension: fixed-dose vs extemporary combinations." Farmeconomia. Health economics and therapeutic pathways 14, no. 4 (2013): 153–60. http://dx.doi.org/10.7175/fe.v14i4.886.

Full text

Abstract:

BACKGROUND: Cardiovascular disease management and prevention represent the leading cost driver in Italian healthcare expenditure. In order to reach the target blood pressure, a large majority of patients require simultaneous administration of multiple antihypertensive agents.OBJECTIVE: To assess the economic impact of the use of fixed dose combinations of antihypertensive agents, compared to the extemporary combination of the same principles.METHODS: A cost minimization analysis was conducted to determine the pharmaceutical daily cost of five fixed dose combinations (olmesartan 20 mg + amlodip

APA, Harvard, Vancouver, ISO, and other styles

23

Battise, Dawn, Cassie L. Boland, and Donald S. Nuzum. "Nebivolol/Valsartan: A Novel Antihypertensive Fixed-Dose Combination Tablet." Annals of Pharmacotherapy 53, no. 4 (2018): 402–12. http://dx.doi.org/10.1177/1060028018813575.

Full text

Abstract:

Data Sources: A PubMed (1966 to October 2018) search was conducted using the following keywords: nebivolol, valsartan, and hypertension (HTN). Additional sources were identified by references. Study Selection and Data Extraction: Articles written in English were included if they evaluated the pharmacology, pharmacokinetics, efficacy, safety, or place in therapy of nebivolol/valsartan in human subjects. Data Synthesis: Most patients with HTN require combination therapy; however, β-adrenergic antagonists and AII type 1 receptor blockers have been considered less effective because of overlapping

APA, Harvard, Vancouver, ISO, and other styles

24

Hume, Anne Lamont, Marilyn McFarland Barbour, Cynthia J. Willey, Annlouise R. Assaf, Kate L. Lapane, and Richard A. Carleton. "Changing Trends in Antihypertensive Therapy in Two New England Communities During the 1980s." Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 13, no. 3 (1993): 244–51. http://dx.doi.org/10.1002/j.1875-9114.1993.tb02732.x.

Full text

Abstract:

The prevalence rates and correlates of antihypertensive drug use among individuals with hypertension were determined using data derived from five biennial population‐based surveys conducted between 1981 and 1990 in two New England communities. Point prevalence estimates were determined for nine categories of antihypertensive agents at five time points, and were analyzed by age and sex using multiple logistic regression. In the first cross‐sectional survey, the prevalence of use per 1000 individuals with hypertension was 235.4 for diuretics, 57.1 for β‐blockers, 65.5 for combination products, 2

APA, Harvard, Vancouver, ISO, and other styles

25

Morozova, T. E., T. B. Andruschishina, and D. G. Shmarova. "Rational pharmacotherapy of hypertension. Urapidil potential." Systemic Hypertension 10, no. 4 (2013): 38–43. http://dx.doi.org/10.26442/sg28982.

Full text

Abstract:

Optimizing pharmacotherapy of arterial hypertension (AH) and varied selection of medicines remains an urgent problem for practitioners. However, despite the large variety of effective antihypertensive drugs, the control of blood pressure levels remains inadequate. Most patients require combined therapy with two or more agents to achieve target blood pressure levels, so the choice of second-line therapy is of particular importance. As adjunctive therapy in patients with uncontrolled hypertension a-blockerscan be used, which, in addition to the antihypertensive effect, have a number of other ben

APA, Harvard, Vancouver, ISO, and other styles

26

Ashcheulova, Tatiana, Nina Gerasimchuk, Olga Kovalyova, and Oleksii Honchar. "Beneficial effects of combined therapy with lacidipine and candesartan in obese hypertensive patients." Romanian Journal of Internal Medicine 56, no. 4 (2018): 257–64. http://dx.doi.org/10.2478/rjim-2018-0018.

Full text

Abstract:

Abstract Introduction. Obesity is becoming one of the leading risk factors of coronary heart disease, hypertension, cerebrovascular disease. Despite the presence of a large number of antihypertensive agents and scientific substantiation of antihypertensive treatment principles it would be wrong to assume that the problem is completely solved. Development of endothelial dysfunction is one of the key pathogenic mechanisms in hypertension. This process is proven to have contributed by immune inflammation activation which is mediated by pro-inflammatory cytokines and oxidative stress. Aims. To inv

APA, Harvard, Vancouver, ISO, and other styles

27

Schekotov, V. V., S. G. Shulkina, A. A. Antipova, O. V. Shanko, and N. L. Kiseleva. "Arterial hypertension in patients with type 1 diabetes mellitus and orthostatic disorders and its correction: Clinical features and possibilities of correction." "Arterial’naya Gipertenziya" ("Arterial Hypertension") 16, no. 4 (2010): 418–22. http://dx.doi.org/10.18705/1607-419x-2010-16-4-418-422.

Full text

Abstract:

Objective. To characterize diabetic nephropathy and cognitive function in patients with arterial hypertension (AH) and diabetes mellitus (DM) type 1, complicated by orthostatic hypotension (OH), and to assess the benefits of venoprotector therapy for the correction of dyscirculatory encephalopathy (DE) and diabetic nephropathy (DN). Design and methods. Sixty patients with AH, DM type 1 and OH were included in the study. Schellongs' orthostatic probe, microalbuminuria (MAU) screening with «Micral-Test-11», Mini Mental State examination (MMSE) test, 10 words memo probe, Spielberg test, Beck ques

APA, Harvard, Vancouver, ISO, and other styles

28

Rosa, Eduardo Cantoni, Maria Tereza Zanella, Nárcia Elisa Bellucci Kohlmann, et al. "Blood pressure and cardiorenal responses to antihypertensive therapy in obese women." Arquivos Brasileiros de Endocrinologia & Metabologia 52, no. 1 (2008): 65–75. http://dx.doi.org/10.1590/s0004-27302008000100010.

Full text

Abstract:

OBJECTIVE: Blood pressure(BP) and target organ responses to antihypertensive drugs are not well established in hypertensive obese patients. This study is aimed at evaluating the effects of obesity and adiposity distribution patterns on these responses. METHODS: 49 hypertensive obese women were designated to different groups according to waist to hip ratio measurements - 37 with troncular and 12 with peripheral obesity. Patients were treated for 24-weeks on a stepwise regimen with cilazapril alone or a cilazapril/hydrochlorothiazide/amlodipine combination therapy to achieve a BP lower than 140/

APA, Harvard, Vancouver, ISO, and other styles

29

Gilyarevsky, Sergey R., Maria V. Golshmid, Nana G. Bendeliani, and Irina M. Kuzmina. "History of combined protection: 25 years of using the fixed-dose combination of amlodipine and bisoprolol in clinical practice." Clinical review for general practice 3, no. 3 (2022): 22–28. http://dx.doi.org/10.47407/kr2022.3.3.00131.

Full text

Abstract:

The paper discusses the role of Concor AM, the fixed-dose combination of amlodipine and bisoprolol, which has been used in clinical practice for treatment of patients with cardiovascular diseases for 25 years. The data are provided on the benefits of using Concor AM in treatment of patients with arterial hypertension and coronary artery disease. Evidence is discussed that illustrated the advantages of using such fixed-dose combination compared to the combination use of amlodipine and bisoprolol in the form of the so-called free combination. The evidence also includes the results of the recentl

APA, Harvard, Vancouver, ISO, and other styles

30

Trishla, Kumar Indrajit, and Anwar Zman Zaki. "Effective Analysis of Enalapril and Amlodipine Combination in Newly Diagnosed Hypertensive Patients a Pharmacoeconomic Comparison of Antihypertensive Drug Efficacy." International Journal of Pharmaceutical and Clinical Research 16, no. 6 (2024): 2615–19. https://doi.org/10.5281/zenodo.14473299.

Full text

Abstract:

At BMIMS Pawapuri Nalanda, Bihar, this study assesses the pharmacoeconomic and therapeutic benefits of combining amlodipine with enalapril in newly diagnosed hypertension patients over a six-month period. One of the medications was given to each of the 100 patients at random, either as combination therapy or as monotherapy. The combination medication group outperformed the monotherapy group in terms of quality of life, patient adherence, and a considerably larger drop in systolic and diastolic blood pressure. Because fewer people were using healthcare services, overall cost-effectiveness incre

APA, Harvard, Vancouver, ISO, and other styles

31

Jain, Peeyush, and S. C. Jha. "Combination therapy for hypertension management: insights from the Indian experts." International Journal of Scientific Reports 10, no. 6 (2024): 200–205. http://dx.doi.org/10.18203/issn.2454-2156.intjscirep20241317.

Full text

Abstract:

Cardiovascular diseases (CVDs) pose a significant global health challenge, with India bearing a disproportionate burden of CVD-related morbidity and mortality. Hypertension (HTN) is a major risk factor for CVDs, affecting nearly 30% of the Indian population. Achieving target blood pressure (BP) levels is crucial for reducing cardiovascular risk, necessitating aggressive antihypertensive therapy. Combination therapy has emerged as a cornerstone in HTN management, especially in high-risk patients. This review delves into the literature and perspectives of Indian cardiologists on combination ther

APA, Harvard, Vancouver, ISO, and other styles

32

Tchernev, Georgi, and Gavrail Poterov. "Antihypertensive Drugs and Cancer: Simultaneously Development of Choroidal Melanoma and Colon Carcinoma after Administration with Valsartan/ Hydrochlorothiazide." Journal of Clinical Research in Dermatology 7, no. 4 (2020): 1–4. http://dx.doi.org/10.15226/2378-1726/7/4/001125.

Full text

Abstract:

Recently published experimental data on the presence of different types of angiotensin receptors in melanoma tissue and in breast cancer, for example, are undoubtedly alarming and indicative because Sartan therapy (in certain groups of patients) may be a risk factor for the patients themselves. The reason for this is the ability of the specific group of drugs to promote carcinogenesis by blocking certain types of receptors, presented in certain types of tumors. The available in vivo and in vitro data in the world literature on the influence of antihypertensive drugs (Sartans and Thiazide diure

APA, Harvard, Vancouver, ISO, and other styles

33

Coleman, E. A., S. K. Coon, R. Kennedy, K. Lockhart, E. J. Anaissie, and B. Barlogie. "Benefits of exercise in combination with epoetin alfa for multiple myeloma." Journal of Clinical Oncology 24, no. 18_suppl (2006): 8605. http://dx.doi.org/10.1200/jco.2006.24.18_suppl.8605.

Full text

Abstract:

8605 Background: Epoetin alfa increases hemoglobin levels and reduces the need for RBC transfusions in diverse groups of patients with cancer-related anemia. Interest in other potential benefits led to this study comparing outcomes relative to the duration of epoetin alfa therapy and exercise for patients receiving intensive therapy for multiple myeloma while enrolled in a randomized, controlled trial of a home-based individualized exercise program. Outcomes of interest included the number of attempts at and days of stem cell collection relative to exercise and the time to recovery post transp

APA, Harvard, Vancouver, ISO, and other styles

34

Cherneva, Aleksandra, and Ivo Petrov. "Novel approaches to treat resistant hypertension." Bulgarian Cardiology 26, no. (1) (2020): 10–34. https://doi.org/10.3897/bgcardio.26.e52712.

Full text

Abstract:

Treatment-resistant hypertension, or resistant hypertension (RH), is defined as arterial hypertension (AH) despite treatment with three properly dosed antihypertensive drugs, at least one of which is a diuretic. Resistant hypertension is associated with an increased incidence of adverse cardiovascular events, renal impairment, and increased mortality. The main treatment of patients with RH is based on maximizing doses of antihypertensive drugs from different groups and adding drugs with complementary mechanisms of action. Despite the combination treatment involving multiple antihypertensive dr

APA, Harvard, Vancouver, ISO, and other styles

35

Suominen, Mari I., Jenni Mäki-Jouppila, Anna Huhtinen, et al. "Additive Benefits of Radium-223 Dichloride and Bortezomib Combination in a Systemic Multiple Myeloma Mouse Model." International Journal of Molecular Sciences 22, no. 11 (2021): 5570. http://dx.doi.org/10.3390/ijms22115570.

Full text

Abstract:

Osteolytic bone disease is a hallmark of multiple myeloma (MM) mediated by MM cell proliferation, increased osteoclast activity, and suppressed osteoblast function. The proteasome inhibitor bortezomib targets MM cells and improves bone health in MM patients. Radium-223 dichloride (radium-223), the first targeted alpha therapy approved, specifically targets bone metastases, where it disrupts the activity of both tumor cells and tumor-supporting bone cells in mouse models of breast and prostate cancer bone metastasis. We hypothesized that radium-223 and bortezomib combination treatment would hav

APA, Harvard, Vancouver, ISO, and other styles

36

Podzolkov, V. I., A. E. Bragina, and K. K. Osadchiy. "A fixed-dose lisinopril+amlodipine+rosuvastatin combination: prospects for its use in patients with hypertension and concomitant dyslipidemia." Terapevticheskii arkhiv 89, no. 12 (2017): 133–40. http://dx.doi.org/10.17116/terarkh20178912133-140.

Full text

Abstract:

In Russia, target blood pressure (BP) levels are achieved in only 14.4% of men and in 30.9% of women. The need for combination therapy of hypertension is as high as 70.7%. There are well-known benefits of combined antihypertensive therapy allowing for higher efficiency and better tolerability. One of the current combinations is a combination of an angiotensin-converting enzyme inhibitor and a calcium antagonist, which have pronounced protective activity and metabolic neutrality. Fixed-dose combinations have substantial advantages over free ones, contributing to improving patient compliance wit

APA, Harvard, Vancouver, ISO, and other styles

37

Shete, Mukesh, Ashish Saxena, Akshay Nakrani, Chirag Shah, Heena Bhojwani, and Dinesh Jiwane. "Assessing cilnidipine and its combination usage in Indian settings: a knowledge, attitude, and practice survey." International Journal of Advances in Medicine 11, no. 6 (2024): 559–65. http://dx.doi.org/10.18203/2349-3933.ijam20243058.

Full text

Abstract:

Background: Hypertension, affecting 31% of the Indian population, is a major risk factor for cardiovascular diseases. Cilnidipine is used in its management, alone or in combination with ARB. The objective of the current KAP survey was to assess the knowledge of healthcare professionals (HCPs) regarding hypertension management, their attitudes toward its treatment, and the application of this knowledge in clinical practice. Method: A pan-India cross-sectional KAP survey was conducted from April 2022 to March 2023. The survey utilized a specially designed questionnaire focusing on various aspect

APA, Harvard, Vancouver, ISO, and other styles

38

Ferdinand, Keith C. "Advances in Antihypertensive Combination Therapy: Benefits of Low-Dose Thiazide Diuretics in Conjunction With Omapatrilat, a Vasopeptidase Inhibitor." Journal of Clinical Hypertension 3, no. 5 (2001): 307–12. http://dx.doi.org/10.1111/j.1524-6175.2001.00488.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Weir, Matthew R., and Rebecca Y. Wang. "Use of angiotensin II receptor blockers alone and in combination with other drugs: a large clinical experience trial." Journal of the Renin-Angiotensin-Aldosterone System 2, no. 1_suppl (2001): S217—S222. http://dx.doi.org/10.1177/14703203010020013801.

Full text

Abstract:

Angiotensin II (Ang II) receptor blockers are the newest class of antihypertensive drugs to be developed. No large-scale clinical trials have been performed to evaluate their efficacy alone, or in combination with other drugs. A large-scale, eight week, open-label, non-placebo-controlled, single-arm trial evaluated the efficacy, tolerability and dose-response of candesartan cilexetil, 16—32 mg once-daily, either as monotherapy or as part of combination therapy, in a diverse hypertensive population in actual practice settings. 6465 patients with high blood pressure, of whom 52% were female and

APA, Harvard, Vancouver, ISO, and other styles

40

Markakis, Konstantinos, Tayiba Alam, Pushpa Jinadev, et al. "Continuous Subcutaneous Insulin Infusion Initiation Is Associated With Blood Pressure Reduction in Adults With Type 1 Diabetes." Journal of Diabetes Science and Technology 13, no. 4 (2019): 691–97. http://dx.doi.org/10.1177/1932296818822818.

Full text

Abstract:

Background: In type 1 diabetes (T1D) continuous subcutaneous insulin infusion (CSII) use has been associated with lower risks for mortality and diabetes-related complications when compared to multiple daily injections. There are limited data on the effect of CSII on blood pressure (BP). We aimed to evaluate the relationship between CSII initiation and BP changes. Methods: We performed a retrospective, single-center, observational study including all adults with T1D who initiated CSII between 2001 and 2014. Mean systolic BP levels were calculated from values obtained up to 15 months before and

APA, Harvard, Vancouver, ISO, and other styles

41

Hallow, K. Melissa, Arthur Lo, Jeni Beh, et al. "A model-based approach to investigating the pathophysiological mechanisms of hypertension and response to antihypertensive therapies: extending the Guyton model." American Journal of Physiology-Regulatory, Integrative and Comparative Physiology 306, no. 9 (2014): R647—R662. http://dx.doi.org/10.1152/ajpregu.00039.2013.

Full text

Abstract:

Reproducibly differential responses to different classes of antihypertensive agents are observed among hypertensive patients and may be due to interindividual differences in hypertension pathology. Computational models provide a tool for investigating the impact of underlying disease mechanisms on the response to antihypertensive therapies with different mechanisms of action. We present the development, calibration, validation, and application of an extension of the Guyton/Karaaslan model of blood pressure regulation. The model incorporates a detailed submodel of the renin-angiotensin-aldoster

APA, Harvard, Vancouver, ISO, and other styles

42

Pirozhenko, A. A., A. S. Ryabtsev, S. V. Shlyk, N. V. Drobotya, and V. V. Kaltykova. "Clinical efficacy of a fixed-dose combination of amlodipine/indapamide/perindopril in patients with hypertension and multiple risk factors." Russian Journal of Cardiology 28, no. 11 (2023): 5682. http://dx.doi.org/10.15829/1560-4071-2023-5682.

Full text

Abstract:

Aim. To evaluate the antihypertensive and organ protective efficacy of the triple fixed-dose combination of amlodipine/indapamide/perindopril in patients with hypertension (HTN) who did not achieve target blood pressure (BP) on previous antihypertensive therapy (AHT).Material and methods. The study included 47 patients with HTN and multiple risk factors who did not achieve target blood pressure during previous AHT. They were prescribed triple fixed-dose combination of amlodipine/indapamide/perindopril with preliminary prescription of amlodipine, indapamide and perindopril in the free-dose comb

APA, Harvard, Vancouver, ISO, and other styles

43

Marfatia, Ravi, William B. White, and Helmut Schumacher. "Effects of Telmisartan with Hydrochlorothiazide versus Valsartan with Hydrochlorothiazide in Patients with Moderate-to-Severe Hypertension." International Journal of Hypertension 2012 (2012): 1–7. http://dx.doi.org/10.1155/2012/976828.

Full text

Abstract:

Combination therapy is recommended for patients with blood pressure (BP) significantly above goal by recent consensus guidelines around the globe. The use of angiotensin II receptor blockers (ARBs) alone or in combination with a thiazide diuretic is a preferred treatment strategy due to both efficacy and safety considerations. However, there are few data known about the benefits of ARB-diuretic combination therapy in patients with moderate-to-severe hypertension. We performed a subanalysis from two large clinical trials that compared the antihypertensive effects of telmisartan 80 mg versus val

APA, Harvard, Vancouver, ISO, and other styles

44

Chang, Tiffany E., Matthew D. Ritchey, Soyoun Park, et al. "National Rates of Nonadherence to Antihypertensive Medications Among Insured Adults With Hypertension, 2015." Hypertension 74, no. 6 (2019): 1324–32. http://dx.doi.org/10.1161/hypertensionaha.119.13616.

Full text

Abstract:

Despite the importance of antihypertensive medication therapy for blood pressure control, no single data system provides estimates of medication nonadherence rates across age groups and health insurance plans types. Using multiple administrative datasets and national survey data, we determined health insurance plan-specific and overall weighted national rates of nonadherence to antihypertensive medications among insured hypertensive US adults in 2015. We used 2015 prescription claims data from Medicare Part D and 3 IBM MarketScan databases (Commercial, Medicaid, Medicare Supplemental) to calcu

APA, Harvard, Vancouver, ISO, and other styles

45

Osadchuk, Mikhail, Inna Vasilieva, Ekaterina Mironova, Nikolay Korzhenkov, and Maxim Trushin. "N-[2-(5-methoxy-1h-indole-3-yl)ethyl]acetamide may correct arterial hypertension in people with sleep problems." Acta Facultatis Medicae Naissensis 40, no. 1 (2023): 54–68. http://dx.doi.org/10.5937/afmnai40-37183.

Full text

Abstract:

Introduction. Sleep disturbance is a frequent complaint of patients suffering from arterial hypertension (AH) for a long time. A hidden and uncontrolled increase in blood pressure (BP) makes the course of physiological processes more difficult, disrupts the regulation of biological rhythms, and increases the risk of cardiovascular complications even with a short duration of AH. At the same time, chronic sleep disorders contribute to the development of hypertension, defining the role of a new socially significant risk factor. An important role in the pathogenesis of insomnia is played by a defi

APA, Harvard, Vancouver, ISO, and other styles

46

Mathew, Ritu A., Samuel Johnson, Shalumol Jose, Shampa Chakraborty, Kenneth N, and Veeranna Gowda. "A comparative study of monotherapy versus combination therapy in patients with stage-1 hypertension in terms of efficacy and cost effectiveness and to assess the medication adherence." International Journal of Research in Pharmaceutical Sciences 9, no. 1 (2018): 147. http://dx.doi.org/10.26452/ijrps.v9i1.1216.

Full text

Abstract:

Hypertension has multiple pathogenesis and majority of patients require two or more antihypertensive drugs to provide optimum control of blood pressure. The aim is to compare the effectiveness of mono therapy versus combination therapy in patients with stage-1 hypertension, to assess the medication adherence and to compare the cost incurred per day for the different therapies. Patient’s demographical details and history was recorded in a data entry form. Outcome of the treatment was measured in terms of reduction in systolic and diastolic blood pressure. Patient’s medication adherence was asse

APA, Harvard, Vancouver, ISO, and other styles

47

Morabito, Gabriella, Federico Rea, Caterina Gregorio, et al. "COST-EFFECTIVENESS OF SINGLE-PILL AND SEPARATE-PILL ADMINISTRATION OF ANTIHYPERTENSIVE TRIPLE-COMBINATION THERAPY: A POPULATION-BASED MICROSIMULATION STUDY." Journal of Hypertension 42, Suppl 1 (2024): e261-e262. http://dx.doi.org/10.1097/01.hjh.0001022184.68536.59.

Full text

Abstract:

Objective: To evaluate the lifetime cost-effectiveness profile of the perindopril/amlodipine/indapamide single-pill combination (SPC) compared with the combination of an angiotensin-converting enzyme inhibitor, a calcium-channel blocker, and a diuretic as a SPC of two drugs plus the third drug separately from the Italian payer perspective. Design and method: A cost-effectiveness analysis was conducted employing multi-state semi-Markov modeling and microsimulation. Using the healthcare utilization database of the Lombardy Region (Italy), 30,172 and 65,817 patients aged >=40 years who initiat

APA, Harvard, Vancouver, ISO, and other styles

48

Semenkova, G. G., and E. E. Matvienko. "Effectiveness and safety of the ACE inhibitor and diuretic combination in postmenopausal women with arterial hypertension." Cardiovascular Therapy and Prevention 10, no. 3 (2011): 35–39. http://dx.doi.org/10.15829/1728-8800-2011-3-35-39.

Full text

Abstract:

Aim. To assess effectiveness, tolerability, and safety of combined antihypertensive therapy (AHT) with an ACE inhibitor (perindopril) and thiazide-like diuretic (indapamide) in postmenopausal women with arterial hypertension (AH). Material and methods. This open, one-centre study included 43 postmenopausal women with AH. For 3 months, the patients in the main group (MG; n=22) received indapamide MR (modified release) (1,5 mg/d) and perindopril. The comparison group (CG; n=21) was administered non-MR indapamide (2,5 mg/d) and perindopril. The dynamics of office blood pressure (BP) levels, 24-ho

APA, Harvard, Vancouver, ISO, and other styles

49

Moriyama, Shohei, Michinari Hieda, Megumi Kisanuki, et al. "Effect of renin–angiotensin system inhibitors in patients with cancer treated with anti-VEGF therapy." Open Heart 9, no. 2 (2022): e002135. http://dx.doi.org/10.1136/openhrt-2022-002135.

Full text

Abstract:

BackgroundCancer treatment with vascular endothelial growth factor signalling pathway (VSP) inhibitors frequently causes hypertension. Although previous reports suggested that the antihypertensive drug renin–angiotensin system inhibitor (RASI) may have a positive synergistic effect with VSP inhibitors, the actual impact on clinical outcomes is unknown.ObjectivesThe study aims to clarify whether RASIs exhibit clinical benefits for patients with cancer with hypertension.MethodFrom the Longevity Improvement and Fair Evidence Study database, comprising Japanese claims data between 2016 and 2020, w

APA, Harvard, Vancouver, ISO, and other styles

50

Leonova, Marina V. "Modern strategy in the treatment of arterial hypertension: combination therapy and fixed combinations." Consilium Medicum 23, no. 6 (2021): 485–90. http://dx.doi.org/10.26442/20751753.2021.6.200942.

Full text

Abstract:

The introduction of fixed combinations for the treatment of arterial hypertension (AH) is an effective strategy to address the public health burden of cardiovascular disease. This strategy is reflected in modern international guidelines for the treatment of AH and is supported by World Health Organization. The use of fixed combinations allows solving key practical problems to achieve better results and improve the prognosis of AH: ensuring the greatest decrease in blood pressure (BP) and a lower target BP level, shortening the time period for obtaining target BP, increasing adherence to treatm

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!